For research use only. Not for therapeutic Use.
PQR-309(Cat No.:I000865)is a dual inhibitor of PI3K and mTOR signaling pathways, both of which play critical roles in cell growth, survival, and metabolism. By targeting these pathways, PQR-309 effectively disrupts cancer cell proliferation and survival, making it a promising candidate for the treatment of various cancers, including solid tumors and hematologic malignancies. Its ability to inhibit both PI3K and mTOR provides a broader therapeutic effect compared to single-target inhibitors. PQR-309 is being investigated in clinical trials for its potential in oncology and combination therapies.
Catalog Number | I000865 |
CAS Number | 1225037-39-7 |
Molecular Formula | C₁₇H₂₀F₃N₇O₂ |
Purity | ≥95% |
Target | PI3K |
Solubility | 10 mM in DMSO |
Storage | -20°C |
IUPAC Name | 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine |
InChI | InChI=1S/C17H20F3N7O2/c18-17(19,20)12-9-13(21)22-10-11(12)14-23-15(26-1-5-28-6-2-26)25-16(24-14)27-3-7-29-8-4-27/h9-10H,1-8H2,(H2,21,22) |
InChIKey | ADGGYDAFIHSYFI-UHFFFAOYSA-N |
SMILES | C1COCCN1C2=NC(=NC(=N2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4 |
Reference | <p style=/line-height:25px/> |